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Abstract
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We report here a distinct mechanism of interaction between topoisomerase I and RNA polymerase
in Mycobacterium tuberculosis and Mycobacterium smegmatis that has evolved independently
from the previously characterized interaction between bacterial topoisomerase I and RNA
polymerase. Bacterial DNA topoisomerase I is responsible for preventing the hyper-negative
supercoiling of genomic DNA. The association of topoisomerase I with RNA polymerase during
transcription elongation could efficiently relieve transcription-driven negative supercoiling. Our
results demonstrate a direct physical interaction between the C-terminal domains of topoisomerase
I (TopoI-CTD) and the β′ subunit of RNA polymerase of M. smegmatis in the absence of DNA.
The TopoI-CTD in mycobacteria are evolutionarily unrelated in amino acid sequence and threedimensional structure to the TopoI-CTD found in the majority of bacterial species outside
Actinobacteria, including Escherichia coli. The functional interaction between topoisomerase I
and RNA polymerase has evolved independently in mycobacteria and E. coli, with distinctively
different structural elements of TopoI-CTD utilized for this protein-protein interaction. Zinc
ribbon motifs in E. coli TopoI-CTD are involved in the interaction with RNA polymerase. For M.
smegmatis TopoI-CTD, a 27 amino acid tail that is rich in basic residues at the C-terminal end is
responsible for the interaction with RNA polymerase. Overexpression of recombinant TopoI-CTD
in M. smegmatis competed with the endogenous topoisomerase I for protein-protein interactions
with RNA polymerase. The TopoI-CTD overexpression resulted in decreased survival following
treatment with antibiotics and hydrogen peroxide, supporting the importance of the protein-protein
interaction between topoisomerase I and RNA polymerase during stress response of mycobacteria.
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Topoisomerases are essential enzymes that are responsible for controlling DNA topology
and facilitating vital cellular processes that include replication, transcription, recombination,
and DNA repair 1–5. The active site for DNA cleavage and rejoining by type IA
topoisomerases is evolutionarily conserved at the N-terminal domains of bacterial
topoisomerase I and topoisomerase III 6, 7. Bacterial topoisomerase I is responsible for
relieving the transcription-driven negative supercoiling, generated behind the RNA
polymerase complex during transcription elongation 8–10. The absence of topoisomerase I
activity in Escherichia coli has been shown to result in increased R-loop formation via the
stable association of the nascent transcript with the unwound DNA 11, 12. This could
potentially block transcription elongation 13, 14. A direct association between RNA
polymerase and topoisomerase I would facilitate gene expression at highly transcribed loci,
including genes induced for survival in stress response.
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It was previously reported that the E. coli RNA polymerase β′ subunit interacts directly with
the zinc ribbon and zinc ribbon-like C-terminal domains (CTD) of topoisomerase I 15, 16. In
E. coli and most bacterial species, the CTD of topoisomerase I have multiple zinc ribbon
domains, each with a Zn(II) ion coordinated by four cysteines 17–19. In contrast, the
topoisomerase I proteins in Actinobacteria, including mycobacteria, evolved with TopoICTD that do not have zinc ribbon or zinc ribbon-like domains 20, 21. Structural
determination by X-ray crystallography showed that the Mycobacterium tuberculosis
topoisomerase I CTD are formed by repeats of a novel protein fold of a four-stranded
antiparallel β-sheet, stabilized by a crossing-over α-helix 22. We speculated that the CTD of
mycobacterial topoisomerase I could be involved in protein-protein interactions, among its
other functions. The protein-protein interactions of topoisomerase I from M. smegmatis
were studied by co-immunoprecipitation (Co-IP) and pull-down assays coupled to tandem
mass spectrometry 23–26. The assays identified an interaction between DNA-dependent RNA
polymerase (RNAP), and topoisomerase I in M. smegmatis. This TopoI-RNAP interaction
also employed the CTD of topoisomerase I, even though the mycobacterial topoisomerase I
CTD do not have zinc ribbons. The conservation of this interaction in M. tuberculosis with a
distinct mode of protein-protein interactions was verified with further studies here.
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Results
Identification of RNAP as protein-protein interaction partner of MsmTopoI
The protein-protein interaction network of the target protein (MsmTopoI) was first analyzed
by Co-IP (Figure 1) coupled to mass spectrometry. Antibodies raised against MtbTopoI also
recognized MsmTopoI (Figure S1). Following SDS-PAGE of the proteins
immunoprecipitated by these antibodies from the soluble lysate of M. smegmatis,
coomassie-stained proteins labeled as a-d in lane 5 of Figure 1B were selected. The control
purified pre-immune antibodies did not precipitate the proteins corresponding to the bands ad, as evident in lane 4 (Figure 1B). The ability of the antibodies raised against MtbTopoI to
immunoprecipitate MsmTopoI from the cell lysate was confirmed by western blot analysis
of the Co-IP eluates (Figure 1C). LC MS/MS analysis identified M. smegmatis RNAP β and
β′ subunits in protein band a (Supplementary material, S5).
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Protein networking of MsmTopoI was further investigated by pull-down assays as described
in Figure 2A with His-tagged MsmTopoI and MsmTopoI-CTD. Coomassie-stained proteins
(e, f in lanes 7 and 8, Figure 2B) of M. smegmatis pulled down by either His-tagged
MsmTopoI or MsmTopoI-CTD, but not control His-Mocr (lane 6, Figure 2B), were analyzed
by LC MS/MS. M. smegmatis RNAP β and β′ subunits were again identified in protein
band e.
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Protein-protein interaction between RNAP and topoisomerase I in M. smegmatis was further
verified by reverse pull-down followed by immunoblotting (Figure 2C). In this assay,
recombinant RNAP β′ subunit (N-terminal 6xHis) was used as a bait to capture
topoisomerase I from the M. smegmatis soluble cell lysate. The assay confirmed a
concentration-dependent binding between the two proteins (lanes 3–5 in Figure 2C). The
combined results from Co-IP and pull-down experiments confirmed the networking of
topoisomerase I and RNAP with a distinct mode of protein-protein interaction that does not
involve the zinc ribbon domains found in other bacterial topoisomerase I.
RNAP-Topoisomerase I interactions are conserved in M. tuberculosis H37Rv

M. smegmatis is a useful model system for the understanding of processes in pathogenic M.
tuberculosis 27, 28. The protein-protein interaction between topoisomerase I and RNAP could
be conserved among these mycobacteria. The RNAP-topoisomerase I interaction in M.
tuberculosis H37Rv was studied by pull-down (Figure 3A) and Co-IP assays (Figure 3B).
Results from both approaches (lane 2 in Figure 3A; lanes 2, 3 in Figure 3B) confirmed the
conservation of the RNAP-topoisomerase I interaction in M. tuberculosis.
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Direct physical interaction between Topoisomerase I and RNAP β′ subunit
The results from the Co-IP and pull-down experiments indicate the presence of
mycobacterial topoisomerase I and RNAP in the same complex. However, a direct physical
interaction between these two partners in the absence of DNA or other mycobacterial
proteins was not established. The direct protein-protein interactions were analyzed with
purified recombinant proteins.
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Physical interaction between the M. smegmatis RNAP β′ subunit and topoisomerase I was
demonstrated by both co-immunoprecipitation (Figure 4A) and pull-down experiments
(Figure 4B). This protein-protein interaction is specific. No interaction with MsmTopoI
could be observed for M. smegmatis RNAP β subunit (Figure 4A). E. coli topoisomerase I,
with CTD that share no homology with MsmTopoI, also did not interact with the M.
smegmatis RNAP β′ subunit (Figure S2).
Mapping of MsmTopoI sequence required for interaction with RNAP
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Pull-down (Figure 5A) and Co-IP (Figure 5B) assays were first conducted to verify that only
the CTD (D5–D8, plus tail at C-terminal end), but not the NTD (D1–D4) of MsmTopoI are
involved in the protein-protein interaction with RNAP. Pull-down assays with purified
recombinant His-tagged proteins retaining different regions of the CTD of MsmTopoI as bait
were then used to further identify the sequence in MsmTopoI-CTD required for pull-down of
RNAP (prey) from the soluble cell extract. The pull-down of RNAP (prey) by proteinprotein interaction could be observed only when the full-length MsmTopoI, or MsmTopoICTD was used as the bait (Figure 5C; lanes 2, 8). Equal molar amounts of the bait protein
(subdomains of topoisomerase I) were used in these assays. MsmTopoI-909t (D1–D8) of
topoisomerase I is only missing the tail at the C-terminal end (last 27 amino acids), but it
still lacks affinity for RNAP. This data indicated that the protein-protein interaction with
RNAP is mediated via the C-terminal tail sequence (amino acids 910-936) of MsmTopoI
(Figure 5D).
Increased sensitivity to antibiotics and oxidative stress from overexpression of MsmTopoICTD
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Overexpression of the MsmTopoI-CTD is expected to inhibit the interaction between native
MsmTopoI and RNAP due to its competition for binding. Following tetracycline-induced
overexpression of recombinant MsmTopoI-CTD in M. smegmatis mc2 155 (Figure 6A), less
full-length MsmTopoI was pulled down by the His-tagged RNAP β′ subunit (Figure 6B).
The MsmTopoI-CTD overexpression did not affect the growth rate in 7H9 media in the
absence of any stress challenge, however, growth rate was reduced by the MsmTopoI-CTD
overexpression in the presence of sublethal concentration of moxifloxacin (Figure S3).
Increased sensitivity to stress challenges from antibiotics (moxifloxacin, streptomycin,
isoniazid) and hydrogen peroxide resulted from the MsmTopoI-CTD overexpression, as seen
from the comparison of the diameters of the zones of inhibition between the control strain
and MsmTopoI-CTD overexpressing strain (Figure 7A). No significant effect from
MsmTopoI-CTD overexpression was observed for sensitivity to rifampicin (data not shown).
This is likely because stress gene transcription is already inhibited by rifampicin. Following
treatment with either moxifloxacin (0.5 μM, 1 μM) or hydrogen peroxide (10 mM, 20 mM),
loss of viability was significantly greater for the MsmTopoI-CTD overexpressing strain
when compared to the control strain (Figure 7B). These results showed that inhibition of the
MsmTopoI-CTD protein-protein interactions can be correlated to enhanced sensitivity to
antibiotics and oxidative stress.
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Discussion
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Most bacterial species have at least two type IA topoisomerases encoded in their
genome 29, 30 to carry out specific associated functions in replication, transcription, and
recombination that require the passage of DNA through a break in a single strand of DNA 3.
TopoI is the only type IA topoisomerase encoded in the genomes of mycobacteria, and has
been shown to be essential for the viability of both M. tuberculosis 31, 32 and M.
smegmatis33. The identification of the protein-protein interaction partners of mycobacterial
TopoI is likely to provide insights into the in vivo functions and regulation of this potential
antibacterial target. It has been reported that the relaxation activity of MtbTopoI and
MsmTopoI can be inhibited by interaction with a MazF homolog 34, as well as Dribokinase 35. The catalytic activity of MtbTopoI can also be modulated by interaction with
the nucleoid associated protein HU 36. These previously identified protein-protein
interactions may be relevant for the regulation of mycobacterial TopoI activity. However,
experimental data on protein-protein interactions of mycobacterial TopoI that may inform on
the physiological setting of its function 37 is currently not available. In this study, we tried to
identify such potential partners present in the total soluble proteins of M. smegmatis using
the approaches of Co-IP and pull-down assays coupled to mass spectrometry. RNAP was
identified as a protein-protein interaction partner for MsmTopoI by both approaches. A
recent ChIP-Seq study showed that M. tuberculosis TopoI and gyrase are recruited to
genomic loci with high transcriptional activity, and MtbTopoI was localized behind RNAP to
be in position for relaxing the negative supercoils generated during transcription 38. Our
studies here demonstrated that M. tuberculosis RNAP can recruit TopoI via protein-protein
interaction to facilitate the co-localization during transcription elongation.
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While protein-protein interaction with the RNAP β′ subunit has been previously reported for
the CTD of E. coli TopoI 15, it should be noted that the CTD of mycobacterial TopoI share
no sequence and structural similarity with the CTD of bacteria outside the Actinobacteria
phylum 39, 21. The CTD of E. coli TopoI are formed by zinc ribbon motifs stabilized by
Zn(II) coordinated with four cysteines in each motif (D5–D7), or zinc ribbon-like motifs of
similar structures (D8–D9) 17, 18. Interaction sites for RNAP have been mapped to E. coli
TopoI CTD regions of D5–D7 as well as D8–D9 15. Analysis of the MsmTopoI protein
sequence 40 and determination of the D1–D5 structure of MtbTopoI 22 have shown that the
CTD of mycobacteria are formed by repeats of a distinctively different structural motif
containing a β-sheet and α-helix, with no Zn(II) present. The results reported here
demonstrate that while the different bacterial species have evolved to have distinct sequences
and structures of the CTD in TopoI, potentially through acquiring different duplicated gene
segments during evolution 41, the protein-protein interaction with the β′ subunit of RNAP
has simultaneously co-evolved through divergent mechanisms in different bacterial phylum.
Molecular simulations predicted that salt bridges and hydrogen bonds formed by basic
residues positioned over a large molecular surface formed by the zinc ribbon motifs of E.
coli TopoI are responsible for interactions with acidic residues in RNAP 16. In contrast, a
distinct mode of protein-protein interaction utilizing a short stretch of C-terminal tail is
employed instead for the TopoI-RNAP interaction in bacteria that do not have Zn(II) binding
TopoI-CTD. As shown in Figure S4, the amino acid sequence of this C-terminal tail is
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highly conserved in mycobacterial TopoI and is rich in basic residues. The basic region
represented by the C-terminal tail of MsmTopoI and MtbTopoI has been proposed to
participate in the binding of DNA to promote strand passage during catalysis 20, 42. Direct
interaction of the C-terminal tail with RNAP would facilitate the rewinding of singlestranded DNA following its exit from the RNAP elongation complex to prevent stabilization
of R-loop structures and inhibition of transcription elongation. The TopoI-RNAP interaction
may be particularly important for efficient transcriptional response to stress conditions to
achieve maximal survival following antibiotics or oxidative challenge 14, 43. Competition for
RNAP interaction by overexpressed recombinant MsmTopoI-CTD may have contributed to
the increase in sensitivity to antibiotics and oxidative stress challenge observed here.
Inhibition of the SOS response induction following moxifloaxcin treatment would result in
the decreased survival for the MsmTopoI-CTD overexpressing strain. Nevertheless, we
cannot rule out that other protein-protein interactions inhibited by overexpressed
MsmTopoI-CTD may also contribute to the increased sensitivity. Other potential proteinprotein interaction partners identified in our Co-IP and pull down experiments are currently
being investigated in further studies. Mycobacterial topoisomerase I may have functional
roles associated with topoisomerase III in bacteria that have this additional type IA
topoisomerase. The actinobacterium Streptomyces coelicolor also does not have
topoisomerase III, and it has been hypothesized that S. coelicolor topoisomerase I is
recruited to ParB complexes because the topoisomerase activity is needed to resolve
segregating chromosomes 44.
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Based on the essentiality of topoisomerase I for the viability of M. tuberculosis, MtbTopoI is
a validated target for discovery of novel TB drugs 32, 45. The SOS response has been shown
to be involved in the induction of mycobacterial resistance to fluoroquinolones 46. Due to its
involvement in transcriptional response to stress challenges, mycobacterial topoisomerase I
inhibitors could be especially useful for use in combination with other antibiotics to increase
the efficacy, and decrease the induction of drug resistance.

Materials and methods
Bacterial strains, plasmids, and cloning

Author Manuscript

M. smegmatis mc2 155 was obtained from ATCC and cultured in 7H9 broth. M. tuberculosis
H37Rv genomic DNA and whole cell lysates were obtained from BEI Resources. A plasmid
pMsmTopoI-CTD for overexpression of topoisomerase I-CTD in M. smegmatis was
constructed by first placing M. smegmatis topA coding sequence (amplified with primers
shown in Table S1) under the control of the tetracycline inducible TetRO promoter in
pKW08 vector 47 via Gibson Assembly cloning 48. Plasmid pMsmTopoI-CTD was then
constructed for overexpression of the C-terminal domains D5–D8 plus tail (residues
627-936) by deleting the N-terminal domains D1–D4 (residues 1-626) via site-directed
mutagenesis. Overexpression of the various domains of M. smegmatis topoisomerase I
(MsmTopoI) in E. coli BL21 STAR DE3 (Invitrogen) was achieved with pET His6 Mocr
TEV LIC cloning vector (2O-T, Addgene Plasmid# 29710). Cloning of recombinant M.
tuberculosis topoisomerase I (MtbTopoI) and its CTD in vector pLIC-HK 49 for expression
in E. coli BL21- CodonPlus(DE3)-RP (Agilent) was described previously 50. Coding
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sequences for M. smegmatis RNAP β (RpoB) and β′ (RpoC) subunits were inserted by
Gibson cloning into the SspI site of pLIC-HK, and transformed into E. coli SoluBL21
(Genlantis) cells for protein expression and purification. The PCR primers used in the
cloning and site-directed mutagenesis are listed in the Supplementary Information (Table S1
and Table S2).
Protein expression and purification
DNA topoisomerase I, sub-domains of topoisomerase I, RNAP β, and RNAP β′ subunits
were purified as recombinant proteins for protein-protein interaction studies. Overexpression
of these recombinant proteins in the E. coli hosts was induced with 1 mM IPTG. Following
the overexpression and cell lysis, recombinant proteins were purified to near homogeneity
by affinity chromatography using Ni-Sepharose 6 Fast flow beads (GE Healthcare Life
Sciences), followed by size-exclusion chromatography.
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Co-Immunoprecipitation (Co-IP)/Tandem Mass spectrometry
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The complex of M. smegmatis topoisomerase I (MsmTopoI) and its potential protein
partners was isolated from the M. smegmatis soluble cell lysate by Co-IP 23. M. smegmatis
mc2 155 was grown to stationary phase in LB-Tween 80 (0.1%). The pelleted cells were
resupsended in lysis/wash buffer (50 mM NaCl, 50 mM NaH2PO4, pH 8.0, 0.1% NP-40),
and then subjected to 5 pulses of sonication (10 seconds/pulse at medium intensity). The
lysate was spun at 16000×g for an hour, and the supernatant soluble lysate was used as prey
in the Co-IP assays. The soluble lysate was pre-incubated (pre-cleared) with protein A/G
plus agarose beads to remove proteins that bind non-specifically to the beads. The precleared lysate (total protein=500 μg) was first mixed with IgG (10 μg) purified from serum
of a rabbit inoculated with MtbTopoI or control pre-immune serum. These rabbit polyclonal
antibodies cross react with MsmTopoI (Figure S1). The protein A/G plus agarose beads
(Santa Cruz Biotechnology), previously equilibrated in wash buffer, was then added to the
lysate-antibody reaction and left overnight at 4°C. On the following day, the reaction
mixture was spun at 700×g, and the supernatant was discarded. The bead pellet with the
bound proteins was washed three times in the wash buffer. The elution of the proteins bound
to the beads was carried out by suspending the bead pellet in 4X SDS sample buffer (240
mM Tris-HCl, 8% SDS, 40% glycerol, 0.04% bromophenol blue), and heating at 95°C for 2
minutes. The eluted proteins (MsmtopoI, and its potential protein partners) were stained
with coomassie blue following SDS-PAGE. The protein bands of interest were excised for
characterization by tryptic digest and mass spectrometry (nano LC/MS/MS) at the
Proteomics and Mass Spectrometry Facility of University of Massachusetts Medical School.
The MS/MS results were searched using Mascot (Matrix Science, London, UK; version
2.5.0) against the UniProt_MSmegmatis_071714 database for trypsin digestion products.
Pull-down assay/Tandem Mass spectrometry
For the pull-down assay 24, the target protein (MsmtopoI) with a fusion tag (N-terminal
6xHistidine) was mixed with M. smegmatis mc2 155 soluble cell extract for 2 hours at 4°C,
and then immobilized on a HisPur Cobalt agarose resin (Thermofisher). The resin with
bound target proteins was washed three times in a pull-down wash buffer (10 mM HEPES,
pH 7.5, 10 mM imidazole, 0.005% Tween-20) to remove the weakly retained proteins. The
J Mol Biol. Author manuscript; available in PMC 2018 September 15.
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proteins that remained bound to the resin were eluted with pull-down elution buffer (10 mM
HEPES, pH 7.5, 350 mM imidazole), separated by SDS-PAGE, and stained with coomassie
blue. The protein bands of interest were excised for identification by tryptic digest and nano
LC/MS/MS.
Reverse pull-down assay/Immunoblotting
A reverse pull-down assay was used to validate the protein interactions identified by pulldown assays. In this assay, a recombinant M. smegmatis RNAP β′ subunit (N-terminal
6xHistidine) was used as bait to pull down topoisomerase I from the soluble cell extract. The
pull-down protocol was similar to that described in the previous section. Western blot
analysis with rabbit polyclonal antibodies against MtbTopoI was used to detect the presence
of topoisomerase I in the eluate.
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Pull-down, Co-IP assays on M. tuberculosis (H37Rv) cell extract
The conservation of RNAP-topoisomerase I protein-protein interactions in M. tuberculosis
was verified by pull-down and Co-IP assays. Whole cell extract of M. tuberculosis H37Rv
was provided by BEI Resources. The extract was spun at 16000×g for 20 min at 4°C, and
the soluble protein fraction was used for the assays. Recombinant MtbTopoI with N-terminal
6x-Histidine was used in the pull-down assay, while antibodies against topoisomerase I were
used in the Co-IP assay as bait to determine if RNAP could be captured from the cell extract.
Following SDS-PAGE, the proteins in the eluates from the assays were immunoblotted with
a monoclonal antibody against RNAP β (Biolegend) which can recognize the RNAP β
subunits 51 across multiple species, including M. tuberculosis and M. smegmatis.
Effect of TopoI-CTD overexpression on sensitivity to antibiotics or hydrogen peroxide
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The M. smegmatis strain overexpressing the CTD of topoisomerase I from the plasmid
pMsmTopA-CTD, or a control M. smegmatis strain transformed with the cloning vector,
were cultured to stationary phase in 7H9 medium containing Hygromycin (100μg/ml) and
tetracycline (25ng/ml). The cultures were adjusted to OD600=1.0 in 7H9 medium, and 200μl
of the OD-adjusted culture was spread on LB plates. Antibiotic or H2O2 was applied to
paper discs placed at the center of the plates, followed by incubation at 37°C for 60 hrs. The
diameter of the zone of inhibition was measured.
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For comparison of viable colony counts following stress challenge, the M. smegmatis strains
were grown in Luria broth-Tween 80 (0.1%) containing Hygromycin (100μg/ml) and
tetracycline (25ng/ml). At the exponential phase, the cultures were treated with
moxifloxacin (0.5 μM or 1 μM) for 12 hours at 37°C. The treated cultures and untreated
cultures were serially diluted and spread on LB plates. The viable colonies were counted,
and the relative viability ratio (treated versus untreated) was calculated. Similarly, viable
colony counts following treatment with hydrogen peroxide (10 mM or 20 mM) was analyzed
with the strains cultured in 7H9 medium containing Hygromycin (100 μg/ml) and
tetracycline (25 ng/ml).
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Refer to Web version on PubMed Central for supplementary material.
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•

Mycobacteria topoisomerase I interacting protein partner of functional
significance

•

Mycobacteria topoisomerase I interacts directly with RNA polymerase beta’
subunit

•

Interaction via short C-terminal tail instead of Zn ribbon motifs in other
bacteria

•

Antibiotics hypersensitivity from topoisomerase I C-terminal domain
overexpression

•

Convergent evolution of topoisomerase I-RNAP interaction via distinct
mechanism
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Figure 1. Co-Immunoprecipitation of topoisomerase I and interacting proteins from M.
smegmatis lysate

(A) Schematic of the Co-IP. (B) Proteins were stained with coomassie blue following SDSPAGE. Lane 1: MW standards; Lane 2: 15 μg of total M. smegmatis proteins in soluble
lysate; Lane 3: purified recombinant MsmTopoI. Proteins were immunoprecipitated from M.
smegmatis lysate (500 μg total proteins) by pre-immune rabbit antibodies (lane 4) or
antibodies raised against MtbTopoI (lane 5). Bands a-d were selected for LC MS/MS
analysis. (C) A fraction of the eluates from Co-IP reactions were electrophoresed on a SDSPAGE and immunoblotted with TopoI antibodies. Lane 1: 25 ng of purified MsmTopoI. The
efficiency of the Co-IP assay was verified by analyzing a small fraction of eluates from the
reaction of M. smegmatis lysate with pre-immune rabbit antibodies (lane 2), or antibodies
raised against MtbTopoI (lane 3).
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Figure 2. Pull-down assay of MsmTopoI-RNAP interaction with HisPur Cobalt agarose resin
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(A) General scheme of the pull-down assay. (B) Proteins pulled down from M. smemgatis
soluble lysate by recombinant N-terminal His-tagged MsmTopoI (lane 8) or MsmTopoICTD (lane 7). His-Mocr, a recombinant viral protein, was used as bait in the control reaction
(lane 6). Lane 1: MW standards; Lane 2: purified recombinant His-Mocr; Lane 3: purified
recombinant His-MsmTopoI-CTD; Lane 4: purified recombinant His-MsmTopoI. (C)
Reverse pull-down of TopoI from M. smegmatis soluble lysate with purified recombinant
RNAP β′ subunit (N-terminal His-tagged). Following SDS-PAGE, the proteins eluted from
the HisPur Cobalt were analyzed by western blot using anti-TopoI antibodies. Lane 1:
purified recombinant MsmTopoI (100 ng); Lane 2: 15 μg of total proteins in M. smegmatis
soluble lysate; Lanes 3–6: eluates from pull-down assay using 500 μg of total proteins in M.
smegmatis soluble lysate with His-tagged RNAP β′ subunit of concentrations 100 nM (lane
3), 50 nM (lane 4), 10 nM (lane 5), and 0 nM (lane 6). The nitrocellulose membrane was
also stained with Ponceau S for detection of the recombinant bait (His-tagged RNAP β′)
used in the assay.
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Figure 3. M. tuberculosis H37Rv topoisomerase I and RNAP are protein-protein interaction
partners

M. tuberculosis RNAP was detected by western blot using a monoclonal antibody against E.
coli RNAP β subunit that cross-reacts with mycobacterial RNAP. (A) Pull-down assay. Lane
1: total soluble lysate of M. tuberculosis H37Rv (10 μg). Eluates from HisPur cobalt resin
incubated with 250 μg of lysate and purified His-tagged MtbTopoI (lane 2), 6xHisMocr
(lane 3) or without any His-tagged protein (lane 4). (B) Co-Immunoprecipitation assay. Lane
1: total soluble lysate of M. tuberculosis H37Rv (10 μg). Immunoprecipitates from 250 μg of
total soluble lysates incubated with IgG against MtbTopoI (lanes 2, 3), no IgG added (lane
4), and IgG from pre-immune serum (lane 5) were analyzed by western blot with the
antibody recognizing RNAP β subunit.
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Figure 4. Direct physical interaction between purified M. smegmatis topoisomerase I and RNAP
β′ subunit

Author Manuscript

(A) Purified RNAP β′ subunit (lanes 1–4), but not β subunit (lanes 6–9), can be coimmunoprecipitated with MsmTopoI. The co-immunoprecipitation reaction contained 100
nM (lanes 1, 6) or 200 nM of MsmTopo I (lanes 2, 7), along with 125 nM of β′ (lanes 1–4)
or β (lanes 6–9) subunit of RNAP. Lanes 3, 8: no MsmTopoI added; Lanes 4, 9: no IgG
added; Lanes 5, 10: purified RNAP subunit (1.5 μg). The proteins in the gel were stained
with coomassie blue following SDS-PAGE. M: Molecular weight standards. (B) Pull-down
assay with HisPur cobalt resin. Lane 1: 25 ng of MsmTopoI. The pull-down reactions
contained 15 nM of His-RNAP β′ subunit incubated with 5, 10, 20, 40, 60, 80 nM (lanes 2–
7) of MsmTopoI. Lane 8: control of 60 nM MsmTopoI with no RNAP β′ subunit added.
MsmTopoI pulled down by His-RNAP β′ subunit was visualized by western blot. The
nitrocellulose membrane was then stained with Ponceau S. M: Protein molecular weight
standards.
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Figure 5. Identification of MsmTopoI sequence required for interaction with RNAP
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(A) M. smegmatis soluble lysate was incubated with the His-tagged recombinant MsmTopoI
or its fragment, and the eluates from the reaction were analyzed by western blotting. TopoICTD, but not TopoI-NTD, can interact with RNAP in M. smegmatis cell lysate. (B) Direct
physical interaction between TopoI-CTD and RNAP β′ subunit was verified by Co-IP assay.
Purified RNAP β′ subunit was incubated with MsmTopoI or its fragment, and the proteins
immunoprecipiated by TopoI antibodies from the reactions were analyzed by SDS-PAGE/
coomassie staining. The assay confirms a physical interaction of RNAP β′ with MsmTopoICTD (lane 6), and not MsmTopoI-NTD (lane 5). Purified RNAP β′, by itself, did not bind to
the antibody (lane 7) or the beads (lane 8). (C) Pull-down assay with MsmTopoI truncation
mutants lacking different segments of the TopoI-CTD. M. smegmatis soluble lysate was
incubated with different constructs of the recombinant MsmTopoI, and the eluates were
probed for the presence of RNAP. The full-length recombinant MsmTopoI (lane 2), and
CTD-MsmTopoI (lane 8) can interact with RNAP. (D) Domain arrangement of MsmTopoI is
shown here. The results from pull-down and Co-IP assays, taken together, demonstrate that
the tail at the C-terminal end of MsmTopoI interacts with RNAP.
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Figure 6. Inhibition of MsmTopoI-RNAP interaction with overexpression of recombinant
MsmTopoI-CTD
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(A) The tetracycline-induced overexpression of MsmTopoI-CTD was confirmed by western
blot analysis with rabbit polyclonal antibodies against TopoI. Lane 1: lysate (10 μg) of M.
smegmatis transformed with control vector. Lane 2: lysate (10 μg) of M. smegmatis
transformed with pMsmTopoI-CTD. (B) Pull-down of MsmTopoI from M. smegmatis lysate
by His-tagged RNAP β′ subunit is reduced by the competing overexpressed MsmTopoICTD. Pull-down of MsmTopoI and MsmtopoI-CTD from the lysate (350 μg) by His-RNAP
β′ (5 nM or 10 nM) was analyzed by western blot using antibodies against MtbTopoI (upper
panel). Lanes 1, 3: pull-down reactions with lysate from the strain transformed with the
control vector (control) in the presence of 5 nM His-RNAP β′ or 10 nM His-RNAP β′.
Lanes 2, 4: pull-down reactions with lysate from the strain overexpressing the MsmTopoICTD (CTD-OE) in the presence of 5 nM His-RNAP β′ or 10 nM His-RNAP β′. Lanes 5, 6:
lysates from either the control strain or the overexpression strain were incubated with the
beads as a negative control for the pull-down assays. Lane 7: lysate (10 μg) from M.
smegmatis transformed with the control vector. Lane 8: lysate (10 μg) from M. smegmatis
overexpressing the MsmTopoI-CTD. The nitrocellulose membrane was stained with Poneau
S (bottom panel) for the detection of the bait (His-RNAP β′).
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Figure 7. Effect of TopoI-CTD overexpression on sensitivity of M. smegmatis to stress challenge
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(A) The tetracycline-induced cultures of the vector control strain (control), and the
MsmTopoI CTD-overexpression strain (CTD-OE) were spread on LB plates, and a blank
paper disc was placed on the plate. 20 μL of the antibiotic solution or hydrogen peroxide
was added to the disc. The plates were incubated at 37°C for 60 hours, and the zone of
inhibition was measured. Error bars represent the standard deviation (n=3). Student’s t-test
was used to calculate the p-values (* p<0.05; ** p<0.005, ***p<0.0005). (B) Following
treatment with moxifloxacin or hydrogen peroxide for 12 hours, the untreated and treated
cultures of the tetracycline-induced vector control strain (control), and MsmTopoI CTDoverexpression (CTD-OE) strain were serially diluted and spread on LB plates. The viable
colony counts (CFU/ml) were determined to calculate the relative survival ratios as the
colony counts of the treated cultures divided by the colony counts of the untreated cultures.
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